The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Epcoritamab combined with GemOx in B-NHL: updated results from EPCORE NHL-2
Raul Cordoba, MD, PhD, Fundación Jiménez Díaz, Madrid, Spain, provides an update on the EPCORE NHL-2 trial (NCT04663347), which investigates epcoritamab combined with gemcitabine and oxaliplatin (GemOx) in B-cell non-Hodgkin lymphoma (B-NHL). As of December 2023, 103 patients had been treated, with two-thirds in their third line or beyond. The overall response rate (ORR) was 85%, with a complete metabolic response (CMR) of 61%. Only one patient experienced grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and one patient experienced grade 3 cytokine release syndrome (CRS). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
